Sequential Multiple Assignment Treatment for Bipolar Disorder
Official Title
Sequential Multiple Assignment Randomized Treatment (SMART) for Bipolar Disorder
Acronym
SMART
Organization
The University of Texas Health Science Center at San AntonioOTHER
Status Module
Record Verification Date
Aug 2020
Overall Recruitment Status or Expanded Access Status
Completed
Last Known Status
Not provided
Delayed Posting
Not provided
Why Stopped
Not provided
Expanded Access Info
No
Start Date
Jun 2011
Primary Completion Date
Dec 2016Actual
Completion Date
Dec 2016Actual
First Submitted Date
Feb 29, 2012
First Submission Date that Met QC Criteria
Apr 30, 2012
First Posted Date
May 1, 2012Estimated
Results Waived
Not provided
Results First Submitted Date
Mar 28, 2018
Results First Submitted that Met QC Criteria
Aug 13, 2020
Results First Posted Date
Aug 14, 2020Actual
Certification/Extension (aka Delayed Results) First Submitted Date
Not provided
Certification/Extension First Submitted that Passed QC Review
Not provided
Certification/Extension First Posted Date
Not provided
Last Update Submitted Date
Aug 17, 2020
Last Update Posted Date
Aug 19, 2020Actual
Sponsor/Collaborators Module
Responsible Party, by Official Title
Sponsor
Lead Sponsor
The University of Texas Health Science Center at San AntonioOTHER
Collaborators
Name
Class
National Institute of Mental Health (NIMH)
NIH
Oversight Module
Has Data Monitoring Committee (DMC)
Yes
Is FDA Regulated Drug
Not provided
Is FDA Regulated Device
Not provided
Is Unapproved Device
Not provided
Pediatric Postmarket Surveillance of a Device Product
Not provided
Product Exported from US
Not provided
FDAAA801 Violation
Not provided
Description Module
Brief Summary
The purpose of this study is to compare which of the two mood stabilizers (drugs that help to steady/stabilize mood in patients with bipolar disorder (BD)), lithium and divalproex, is more effective in patients with bipolar disorder over 26 weeks. The study will also compare if lithium or divalproex used alone versus lithium or divalproex used with quetiapine versus lithium or divalproex used with lamotrigine is more effective when symptoms of depression develop.
Detailed Description
This open methods advancement study will randomize BD patients with clinically significant symptoms to treatment with one of two mood stabilizers (MS), lithium [Li] or divalproex [Div]. Those who develop protocol defined depression will then be randomized to a MS alone, MS + quetiapine [QTP] or MS + lamotrigine [LTG]. A SMART strategy employs a rule for adding new treatments based on each patient's current illness state and response during the trial, mimicking the adaptive nature of treatment selection which occurs in clinical settings, but in a controlled way which allows application of causal inference. By using early indices of response to dynamically alter treatment decisions to improve outcome, SMART eliminates unmeasured confounders associated with treatment decisions that are not randomized, as occurs in data mining exercises and in other non-randomized decisions in studies which randomize one variable at baseline. This sequential adaptive design represents a methodological innovation in bipolar trial history which will have particular implications for effectiveness studies.
Specific Aim A.1: Assess the feasibility of a SMART design in the conduct of an effectiveness study over 26 weeks in patients with BD (bipolar disorder).
Aim A.2 Compare the effectiveness of Li to Div as a primary component of treatment for BD over 26 weeks.
Aim A.3: Assess the effectiveness of MS + QTP and MS + LTG versus MS in subjects who develop depression.
A4. Exploratory Aims: 1.Determine the effects of ethnicity, language facility, education and stress as moderators of treatment outcomes; 2. Explore the use of novel statistical methodologies to more informatively characterize illness trajectories in response to the interventions. In the aggregate these aims also will clarify whether the SMART confirms results provided by traditional, single point randomized controlled trials (RCTs).
Conditions Module
Conditions
Bipolar I Disorder
Bipolar II Disorder
Keywords
Not provided
Design Module
Study Type
Interventional
Number of References to an Expanded Access Study
Not provided
Expanded Access Types
Not provided
Patient Registry
Not provided
Target Follow-Up Duration
Not provided
Phases
Phase 4
Interventional Study Design
Allocation
Biospecimen
No data available
No data is available for this block.
Enrollment
112Actual
Arms/Interventions Module
Arm Groups
Label
Type
Description
Intervention Names
Lithium
Active Comparator
This open methods advancement study will randomize BD patients with clinically significant symptoms to treatment with one of two mood stabilizers, lithium [Li] at baseline. Lithium is one of these two mood stabilizers. The person may or may not stay solely on lithium throughout the study.
Drug: Lithium
Divalproex
Active Comparator
This open methods advancement study will randomize BD patients with clinically significant symptoms to treatment with one of two mood stabilizers, divalproex (DV)at baseline. Divalproex is one of these two mood stabilizers. The person may or may not stay solely on divalproex throughout the study.
Drug: Divalproex
Lithium plus Quetiapine
Active Comparator
Those who develop protocol defined depression will then be randomized to a mood stabilizer (lithium) + quetiapine [QT].
Drug: Lithium
Drug: Quetiapine
Lithium plus Lamotrigine
Active Comparator
Those who develop protocol defined depression will then be randomized to a mood stabilizer (lithium) + lamotrigine (LM).
Drug: Lithium
Drug: Lamotrigine
Divalproex plus Quetiapine
Active Comparator
Interventions
Name
Type
Description
Arm Group Labels
Other Names
Lithium
Drug
Therapeutic dosage as indicated by participants condition with blood levels. LI will be dosed to attain Li of ≥0.5mEq/L (milliequivalents per liter).
Lithium
Outcomes Module
Primary Outcomes
Measure
Description
Time Frame
Bipolar Inventory of Symptoms Scale (BISS)
The BISS uses a structured interview to assess the full spectrum of symptoms associated with all primary clinical states in bipolar disorder, yielding a total severity, a depression, a mania, as well as dimensional scale scores. There are 42 items; each item is rated on a 0-4 scale. The BISS is a clinician-rated instrument. The Scale is rated as follows:
0 Not at all
Slight
Mild
Moderate
Severe Each of the 42 items is rated separately, with a score, based on the most recent 7 day period. The mean score is calculated from the total score, giving an overall score out of 4, where 0 is slight and 4 is the most severe symptoms. A negative score indicated an improvement from baseline to 26 weeks.
Change from Baseline to 26 weeks
Secondary Outcomes
Measure
Description
Time Frame
Global Assessment of Functioning
The Clinical Global Impression-Severity Scale (CGI-S) is used to assess global illness severity
The CGI-S score change is measured from baseline to 26 weeks and is rated on a 7-point scale. The scale is read as follows:
very much improved since the initiation of treatment
much improved
minimally improved
no change from baseline (the initiation of treatment)
minimally worse
much worse
very much worse since the initiation of treatment The score is calculated as a mean of all items, where 1 indicates improvement from inititation of visit, and 7 indicates the condition to be much worse since the inititation of treatment. A negative score indicates a change from worse to better.
Other Outcomes
Not provided
Eligibility Module
Eligibility Criteria
Inclusion Criteria:
DSM-IV TR (Diagnostic and Statistical Manual Edition IV Text Revision) diagnosis BD I or II as assessed by MINI PLUS (Mini International Neuropsychiatric Interview PLUS)
Male or female ≥ 18 years old
Currently symptomatic with a CGI-BP-S ≥3 for mania/hypomania &/or depression for ≥ 2 weeks
One of the following indicators of recent active illness: a depressive or manic or hypomanic or mixed episode in the past 12 months
If female of child bearing age must use effective birth control.
Exclusion Criteria:
Unwilling or unable to comply with study requirements
Renal impairment (serum creatinine > 1.5 mg/dL)
If maintained on thyroid medication must be euthyroid for at least 1 month before Visit 1
Patients who have had intolerable side effects to QTP, Li, Div, or LTG
Patients whose clinical status requires inpatient care
Drug/alcohol dependence within the past 30 days
Pregnancy as determined by serum pregnancy test or breastfeeding
History of poor response to Li at a serum Li of ≥ 0.5 mEq/L (milliequivalents per Liter) or Div at a serum level of ≥ 45 mg/dL for at least 2 weeks.
Hashimoto Y, Kotake K, Watanabe N, Fujiwara T, Sakamoto S. Lamotrigine in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev. 2021 Sep 15;9(9):CD013575. doi: 10.1002/14651858.CD013575.pub2.
See Also Links
Not provided
Available IPD Information
Not provided
IPD Sharing Statement Module
No data available
No data is available for this block.
After a washout period of up to 1 week, subjects will be openly randomized to treatment with Lithium (Li) or Divalproex (Div) for 2 weeks. Subjects who become intolerant to lithium or divalproex at any point will be crossed over to the other mood stabilizer and continued in the study, or terminate early.
Recruitment Details
Not provided
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
FG000
Randomization to Lithium
Subjects enrolled will be randomized to one of two mood stabilizers, Lithium (Li) or Divalproex (Div) in Randomization 1. If subjects show no symptoms, they will complete at the end of this phase of treatment.
FG001
Randomization to Divalproex
Subjects enrolled will be randomized to one of two mood stabilizers, Lithium (Li) or Divalproex (Div) in Randomization 1. If subjects show no symptoms, they will complete at the end of this phase of treatment.
FG002
Monotherapy Li or Div Plus Quetiapine
Subjects who were on Li or Div and developed symptoms of depression had Quetiapine added to their treatment regimen
FG003
Monotherapy Li or Div Plus Lamotrigine
Subjects who were on monotherapy Li or Div who developed symptoms of depression had Lamotrigine added to their regimen
Periods
Title
Milestones
Reasons Not Completed
Randomization 1
Type
Comment
Milestone Data
STARTED
Not all subjects were eligible to progress to from Randomization 1 to 2 based on depression symptoms
FG00053 subjects
FG00159 subjects
FG0020 subjectsNo subject assigned during first randomization to monotherapy
FG0030 subjectsNo subject assigned during first randomization to monotherapy
COMPLETED
FG00030 subjects
FG00143 subjects
FG0020 subjects
FG0030 subjects
NOT COMPLETED
FG00023 subjects
FG00116 subjects
FG0020 subjects
FG0030 subjects
Randomization 2
Type
Comment
Milestone Data
STARTED
Some subjects completed at the end of Randomization 1 and did not progress to randomization 2
FG00021 subjectsSome subjects who completed the first randomization had QTP or LTG added to regimen
FG00131 subjectsSome subjects who completed the first randomization had QTP or LTG added to regimen
FG00217 subjectsAssignment of Quetiapine plus monotherapy for symptoms of depression
Baseline Characteristics Module
Baseline Analysis Population Description
Not provided
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
BG000
Randomization to Divalproex
Subjects randomized to Divalproex at Randomization 1. Demographics were only tracked in the Randomization 1 phase.
BG001
Randomization to Lithium
Denominators
Units
Counts
Participants
BG000
Baseline Measures
Title
Description
Population Description
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Denominator Units Selected
Denominators
Classes
Age, Customized
Count of Participants
Outcome Measures Module
Outcome Measures
Type
Title
Description
Population Description
Reporting Status
Anticipated Posting Date
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Time Frame
Units Analyzed
Denominator Units Selected
Arm/Group Information
Denominators
Classes
Analyses
Primary
Bipolar Inventory of Symptoms Scale (BISS)
The BISS uses a structured interview to assess the full spectrum of symptoms associated with all primary clinical states in bipolar disorder, yielding a total severity, a depression, a mania, as well as dimensional scale scores. There are 42 items; each item is rated on a 0-4 scale. The BISS is a clinician-rated instrument. The Scale is rated as follows:
0 Not at all
Slight
Mild
Moderate
Severe Each of the 42 items is rated separately, with a score, based on the most recent 7 day period. The mean score is calculated from the total score, giving an overall score out of 4, where 0 is slight and 4 is the most severe symptoms. A negative score indicated an improvement from baseline to 26 weeks.
Posted
Mean
Standard Deviation
calculated mean scale score
Change from Baseline to 26 weeks
ID
Title
Description
OG000
Divalproex After Randomization 1
After a washout period of up to 1 week, subjects will be openly randomized to treatment Divalproex for 2 weeks. Subjects who become intolerant to or divalproex at any point will be crossed over to the other mood stabilizer (Lithium) and continued in the study.
Adverse Events Module
Frequency Threshold
0
Time Frame
Not provided
Description
Adverse events were only collected for Lithium and Divalproex interventions. Adverse events were not tracked for monotherapy plus QTP or LTG (in Randomization 2 of the study).
All-Cause Mortality Comment
Not provided
Arm/Groups
ID
Title
Description
Deaths (Affected)
Deaths (At Risk)
Serious Events (Affected)
Serious Events (At Risk)
Other Events (Affected)
Other Events (At Risk)
EG000
Divalproex
After a washout period of up to 1 week, subjects will be openly randomized to treatment Divalproex for 2 weeks. Subjects who become intolerant to or divalproex at any point will be crossed over to the other mood stabilizer (Lithium) and continued in the study. Adverse events were not collected for Randomization 2.
Serious Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Shortness of Breath
Cardiac disorders
Non-systematic Assessment
Other Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Nausea and Vomiting
Gastrointestinal disorders
Non-systematic Assessment
More Info Module
Limitations and Caveats
Not provided
Certain Agreements
Are all PI(s) employees of the sponsor?
No
Restriction Type
Point of Contact
Title
Organization
Phone
Extension
Email
Charles Bowden, MD
UT Health San Antonio
2105675393
bowdenc@uthscsa.edu
Jul 10, 2026
Removed Countries
Not provided
Submission Tracking
No data available
No data is available for this block.
Condition Browse Module
MeSH Terms
ID
Term
D001714
Bipolar Disorder
Ancestor Terms
ID
Term
D000068105
Bipolar and Related Disorders
D019964
Mood Disorders
D001523
Mental Disorders
Browse Leaves
Not provided
Browse Branches
Not provided
Intervention Browse Module
MeSH Terms
ID
Term
D008094
Lithium
D016651
Lithium Carbonate
D014635
Valproic Acid
D000077213
Lamotrigine
D000069348
Quetiapine Fumarate
Ancestor Terms
ID
Term
D008672
Metals, Alkali
D004602
Elements
D007287
Inorganic Chemicals
D019565
Metals, Light
Browse Leaves
Not provided
Browse Branches
Not provided
Randomized
Intervention Model
Parallel Assignment
Intervention Model Description
Not provided
Primary Purpose
Treatment
Observational Model
Not provided
Time Perspective
Not provided
Masking Info
Masking
None (Open Label)
Masking Description
Not provided
Who Masked
Not provided
Those who develop protocol defined depression will then be randomized to a mood stabilizer (divalproex) + quetiapine [QT].
Drug: Divalproex
Drug: Quetiapine
Divalproex plus Lamotrigine
Active Comparator
Those who develop protocol defined depression will then be randomized to a mood stabilizer (divalproex) + lamotrigine (LM).
Drug: Divalproex
Drug: Lamotrigine
Lithium plus Lamotrigine
Lithium plus Quetiapine
Lithium Carbonate
Divalproex
Drug
DV will be dosed to attain DV levels of ≥45mg/L.
Divalproex
Divalproex plus Lamotrigine
Divalproex plus Quetiapine
Depakote
Depakote ER
Lamotrigine
Drug
LM will be incrementally dosed up to 400 mg/day, or, in combination with DV, 200 mg/day. Dosage may be reduced for adverse effects to one half of the target dose.
Divalproex plus Lamotrigine
Lithium plus Lamotrigine
Lamictal
Quetiapine
Drug
QT will be started at 50 mg/day and titrated up to 300 mg as tolerated. QT will be discontinued if not tolerated at 100mg/day and the patient will be treated according to guidelines.
Divalproex plus Quetiapine
Lithium plus Quetiapine
Seroquel
Change from Baseline to 26 weeks
Baseline Randomization Percentage of Bipolar Types
Percentages of Type I and Type II Bipolar Disorder included in Randomization groups
Baseline
Demographic in Randomization 1 Group
Baseline demographic percentages of subject randomized to either Divalproex or Lithium at the first randomization
Baseline
San Antonio
Texas
78229-3900
United States
FG00318 subjectsAssignment of Lamotrigine plus monotherapy for symptoms of depression
COMPLETED
FG0001 subjects
FG0013 subjects
FG00212 subjects
FG00313 subjects
NOT COMPLETED
FG00020 subjects
FG00128 subjects
FG0025 subjects
FG0035 subjects
Subjects randomized to Lithium at Randomization 1. Demographics were only tracked in the Randomization 1 phase.
BG002
Total
Total of all reporting groups
59
BG00153
BG002112
Participants
Title
Denominators
Categories
Subjects over 18 years old
Title
Measurements
BG00059
BG00153
BG002112
Sex: Female, Male
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Female
BG00037
BG00132
BG00269
Male
BG00022
BG00121
BG00243
Race/Ethnicity, Customized
Count of Participants
Participants
Title
Denominators
Categories
Overall Total
Title
Measurements
African American
BG0008
BG0017
BG00215
White (non Hispanic)
BG00033
BG00126
BG00259
Hispanic
BG00015
BG00119
BG00234
Asian/Asian American
BG0001
BG0011
BG0022
Other
BG0002
BG0010
BG0022
Region of Enrollment
Count of Participants
Participants
Title
Denominators
Categories
United States
Title
Measurements
BG00059
BG00153
BG002112
OG001
Lithium After Randomization 1
After a washout period of up to 1 week, subjects will be openly randomized to treatment Lithium for 2 weeks. Subjects who become intolerant to or Lithium at any point will be crossed over to the other mood stabilizer (Divalproex) and continued in the study.
OG002
Divalproex or Lithium Monotherapy
Group which continued monotherapy or divalproex after Randomization 2
OG003
Lithium or Divalproex Plus Quetiapine
Group which had Quetiapine added to Lithium of Divalproex
OG004
Lithium or Divalproex Plus Lamotrigine
Group which had Lamotrigine added to Lithium or Quetiapine
Units
Counts
Participants
OG00059
OG00153
OG00217
OG00317
OG00418
Title
Denominators
Categories
Mania
Title
Measurements
OG000-0.31± NAStandard deviation is unavailable since the PI and statistician have retired and the information is unavailable.
OG001-0.41± NAStandard deviation is unavailable since the PI and statistician have retired and the information is unavailable.
OG0020.15± NAStandard deviation is unavailable since the PI and statistician have retired and the information is unavailable.
OG003-0.38± NAStandard deviation is unavailable since the PI and statistician have retired and the information is unavailable.
OG004-0.85± NAStandard deviation is unavailable since the PI and statistician have retired and the information is unavailable.
Depression
Title
Measurements
OG000-0.71± NAStandard deviation is unavailable since the PI and statistician have retired and the information is unavailable.
OG001-0.20± NAStandard deviation is unavailable since the PI and statistician have retired and the information is unavailable.
OG002-0.18± NAStandard deviation is unavailable since the PI and statistician have retired and the information is unavailable.
Irritability
Title
Measurements
OG000-0.50± NAStandard deviation is unavailable since the PI and statistician have retired and the information is unavailable.
OG001-0.39± NAStandard deviation is unavailable since the PI and statistician have retired and the information is unavailable.
OG002-0.27± NAStandard deviation is unavailable since the PI and statistician have retired and the information is unavailable.
Anxiety
Title
Measurements
OG000-0.49± NAStandard deviation is unavailable since the PI and statistician have retired and the information is unavailable.
OG001-0.51± NAStandard deviation is unavailable since the PI and statistician have retired and the information is unavailable.
OG0020.16± NAStandard deviation is unavailable since the PI and statistician have retired and the information is unavailable.
Psychosis
Title
Measurements
OG000-0.14± NAStandard deviation is unavailable since the PI and statistician have retired and the information is unavailable.
OG001-0.25± NAStandard deviation is unavailable since the PI and statistician have retired and the information is unavailable.
OG002-0.27± NAStandard deviation is unavailable since the PI and statistician have retired and the information is unavailable.
Secondary
Global Assessment of Functioning
The Clinical Global Impression-Severity Scale (CGI-S) is used to assess global illness severity
The CGI-S score change is measured from baseline to 26 weeks and is rated on a 7-point scale. The scale is read as follows:
very much improved since the initiation of treatment
much improved
minimally improved
no change from baseline (the initiation of treatment)
minimally worse
much worse
very much worse since the initiation of treatment The score is calculated as a mean of all items, where 1 indicates improvement from inititation of visit, and 7 indicates the condition to be much worse since the inititation of treatment. A negative score indicates a change from worse to better.
Posted
Mean
Standard Deviation
calculated mean scale score
Change from Baseline to 26 weeks
ID
Title
Description
OG000
Divalproex After Randomization 1
After a washout period of up to 1 week, subjects will be openly randomized to Divalproex. Subjects who become intolerant to Divalproex at any point will be crossed over to the other mood stabilizer (Lithium) and continued in the study.
OG001
Lithium After Randomization 1
After a washout period of up to 1 week, subjects will be openly randomized to Lithium. Subjects who become intolerant to or lithium at any point will be crossed over to the other mood stabilizer (divalproex) and continued in the study.
OG002
Divalproex or Lithium Monotherapy
Group which continued monotherapy on Divalproex or Lithium
OG003
Lithium or Divalproex Plus Quetiapine
Group which had Quetiapine added to Lithium or Divalproex
OG004
Lithium or Divalproex Plus Lamotrigine
Group which had Lamotrigine added to Lithium or Divalproex
Units
Counts
Participants
OG00059
OG00153
OG00217
OG003
Title
Denominators
Categories
CGI-Depression
Title
Measurements
OG000-1.11± NAPI and statistician have retired and do not have access to the data
OG001-0.32± NAPI and statistician have retired and do not have access to the data
OG002
Secondary
Baseline Randomization Percentage of Bipolar Types
Percentages of Type I and Type II Bipolar Disorder included in Randomization groups
Posted
Number
percentage of participants
Baseline
ID
Title
Description
OG000
Bipolar Type 1 Divalproex Group
Percentage of Bipolar Type 1 included in Randomization 1
OG001
Bipolar Type II Divalproex Group
Percentage of Bipolar Type II included in Randomization 1
OG002
Bipolar Type 1 Lithium Group
Percentage of Bipolar Type 1 included in Randomization 1
OG003
Bipolar Type II Lithium Group
Percentage of Bipolar Type II included in Randomization 1
Units
Counts
Participants
OG00059
OG00153
OG00259
OG00353
Title
Denominators
Categories
Title
Measurements
OG00070
OG00174.1
OG00230
OG003
Secondary
Demographic in Randomization 1 Group
Baseline demographic percentages of subject randomized to either Divalproex or Lithium at the first randomization
Posted
Number
percentage of subjects
Baseline
ID
Title
Description
OG000
Divalproex
Subjects randomized to Divalproex at the first randomization
OG001
Lithium
Subjects randomized to Lithium at the first randomization.
Units
Counts
Participants
OG00059
OG00153
Title
Denominators
Categories
Single never married
Title
Measurements
OG00027.1
OG00133.3
Married
Title
Measurements
OG000
1
59
19
59
EG001
Lithium
After a washout period of up to 1 week, subjects will be openly randomized to treatment Lithium for 2 weeks. Subjects who become intolerant to or Lithium at any point will be crossed over to the other mood stabilizer (Divalproex) and continued in the study. Adverse events were not collected for Randomization 2.
1
53
15
53
EG0001 events1 affected59 at risk
EG0010 events0 affected53 at risk
Neurological symptoms
Nervous system disorders
Non-systematic Assessment
Headache, drowsiness, thirst
EG0000 events0 affected59 at risk
EG0011 events1 affected53 at risk
EG00019 events19 affected59 at risk
EG00115 events15 affected53 at risk
Not provided
Results Disclosure Restriction on PI(s)?
No
Other Details
Not provided
D008670
Metals
D002254
Carbonates
D000468
Alkalies
D002255
Carbonic Acid
D017554
Carbon Compounds, Inorganic
D018020
Lithium Compounds
D010421
Pentanoic Acids
D014631
Valerates
D000144
Acids, Acyclic
D002264
Carboxylic Acids
D009930
Organic Chemicals
D005232
Fatty Acids, Volatile
D005227
Fatty Acids
D008055
Lipids
D014227
Triazines
D006573
Heterocyclic Compounds, 1-Ring
D006571
Heterocyclic Compounds
D003987
Dibenzothiazepines
D013841
Thiazepines
D013846
Thiepins
D013457
Sulfur Compounds
D006575
Heterocyclic Compounds, 3-Ring
D000072471
Heterocyclic Compounds, Fused-Ring
OG003-0.61± NAStandard deviation is unavailable since the PI and statistician have retired and the information is unavailable.
OG004-0.95± NAStandard deviation is unavailable since the PI and statistician have retired and the information is unavailable.
OG003-0.66± NAStandard deviation is unavailable since the PI and statistician have retired and the information is unavailable.
OG004-0.96± NAStandard deviation is unavailable since the PI and statistician have retired and the information is unavailable.
OG003-0.72± NAStandard deviation is unavailable since the PI and statistician have retired and the information is unavailable.
OG004-0.93± NAStandard deviation is unavailable since the PI and statistician have retired and the information is unavailable.
OG003-0.14± NAStandard deviation is unavailable since the PI and statistician have retired and the information is unavailable.
OG004-0.16± NAStandard deviation is unavailable since the PI and statistician have retired and the information is unavailable.
17
OG00418
-0.09
± NA
PI and statistician have retired and do not have access to the data
OG003-0.99± NAPI and statistician have retired and do not have access to the data
OG004-1.24± NAPI and statistician have retired and do not have access to the data
CGI-Mania
Title
Measurements
OG000-0.69± NAPI and statistician have retired and do not have access to the data
OG001-1.12± NAPI and statistician have retired and do not have access to the data
OG002-0.19± NAPI and statistician have retired and do not have access to the data
OG003-0.71± NAPI and statistician have retired and do not have access to the data
OG004-1.81± NAPI and statistician have retired and do not have access to the data
CGI-Overall
Title
Measurements
OG000-1.28± NAPI and statistician have retired and do not have access to the data
OG001-0.55± NAPI and statistician have retired and do not have access to the data
OG002-0.11± NAPI and statistician have retired and do not have access to the data
OG003-0.99± NAPI and statistician have retired and do not have access to the data
OG004-1.64± NAPI and statistician have retired and do not have access to the data